Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice

Nephrology Dialysis Transplantation

Volumn 23, Issue 5, 2008, Pages 1513-1520

  Desai, Anjali ^a   Zhao, Ying ^a   Warren, Jeffrey S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Dimethylarginine dimethylaminohydrolase; Dimethylarginines; Endothelial cells; Erythropoietin; Nitric oxide

Indexed keywords

DIMETHYLARGININASE; N(G),N(G) DIMETHYLARGININE; NITRATE; NITRIC OXIDE; NITRITE; RECOMBINANT ERYTHROPOIETIN;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE; UMBILICAL VEIN; UPREGULATION; WESTERN BLOTTING;

AMIDOHYDROLASES; ANIMALS; ARGININE; BASE SEQUENCE; CELLS, CULTURED; DNA PRIMERS; ENDOTHELIAL CELLS; EPOETIN ALFA; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; LIVER; MALE; MICE; MICE, INBRED BALB C; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; UP-REGULATION; VASCULAR DISEASES;

EID: 44449163363     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm869     Document Type: Article

References (23)

1. US Renal Data System. USRDS Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, 2002
2. Schmidt RJ, Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int 2000; 58: 1261-1266
3. Boeger R, Zoccali C. ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atheroscler Suppl 2003; 4: 23-28
4. Fliser D. Asymmetric dimethylarginine (ADMA): the silent transition from a 'uraemic toxin' to a global cardiovascular risk molecule. Eur J Clin Invest 2005; 35: 71-79
5. Thum T, Tsikas D, Stein S et al. Suppression of endothelial progenitor cells in human coronary artery disease by endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol 2006; 46: 1693-1701
6. Zoccali C, Bode-Böger SM, Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-2117
7. Singh A, Szczech L, Tang KL et al. Correction of anemiawith Epoetin Alfa in Chronic Kidney Disease. New Engl J Med 2006; 355: 2085-2089
8. Maiese K, Li F, Chong Z. New avenues of exploration for erythropoietin. JAMA 2005; 293: 90-95
9. Wang XQ, Vaziri ND. Erythropoietin depresses nitric oxide synthase expression by endothelial cells. Hypertension 1999; 33: 894-899
10. Desai A, Zhao Y, Lankford HA et al. Nitric oxide suppresses EPO-induced monocyte chemoattractant protein-1 in endothelial cells: implications for atherogenesis in chronic renal disease. Lab Invest 2006; 86: 369-379
11. Chan JR, Boeger RH, Bode-Boeger SM et al. Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. Arterioscler Thromb Vasc Biol 2000; 20: 1040-1046
12. Boeger R, Bode-Boeger SM, Tsao PS et al. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 2000; 36: 2287-2295
13. Whitesall SE, Hoff JB, Vollmer AP et al. Comparison of simultaneous measurement of mouse systolic arterial blood pressure by radiotelemetry and tail-cuff methods. Am J Physiol 2004; 286: H2408-H2415
14. Stühlinger MC, Tsao PS, Her J et al. Homocysteine impairs the nitric oxide synthase pathway. Circulation 2001; 104: 2569-2575
15. Saran R, Novak JE, Desai A et al. Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study. Nephrol Dial Transplant 2003; 18: 2415-2420
16. Leiper JM, Santa Maria J, Chubb A et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999; 343: 209-214
17. Scalera F, Kielstein JT, Martens-Lobenhoffer J et al. Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylargingine dimethylaminohydrolase. J Am Soc Nephrol 2005; 16: 892-898
18. Bieber E. Erythropoietin, the biology of erythropoiesis and epoetin alfa. An overview. J Reprod Med 2001; 46: 521-530
19. Billecke SS, Kitzmiller LA, Northrup JJ et al. Contribution of whole blood to the control of plasma asymmetrical dimethylarginine. Am J Physiol Heart Circ Physiol 2006: H1788-H1796
20. Kielstein JT, Zoccali C. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? Am J Kidney Dis 2005; 46: 186-202
21. Tsukahara H, Hiraoka M, Hori C et al. Chronic erythropoietin treatment enhances endogenous nitric oxide production in rats. Scand J Clin Lab Invest 1997; 57: 487-494
22. Kanagy NL, Perrine MF, Cheung DK et al. Erythropoietin administration in vivo increases vascular nitric oxide synthase expression. J Cardiovasc Pharmacol 2003; 42: 527-533
23. Ruschitzka FT, Wenger R RH, Stallmach T et al. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci USA 2000; 97: 11609-11613